Low-Dose Naltrexone Is Not Recommended for Treating Inflammatory Activity in Multiple Sclerosis
Low-dose naltrexone (LDN) should not be used as a treatment for inflammatory activity in multiple sclerosis, as it lacks FDA approval for this indication, is not mentioned in any MS treatment guidelines, and has insufficient evidence demonstrating efficacy on objective measures of disease activity, morbidity, or mortality.
Why LDN Is Not Appropriate
Absence from Treatment Guidelines and FDA Approval
The FDA-approved indication for naltrexone is limited to opioid and alcohol dependence at standard doses of 50 mg daily 1. No established MS treatment guidelines—including the comprehensive 2015 MAGNIMS consensus guidelines on MRI monitoring and the 2025 ECTRIMS/EBMT guidelines on advanced therapies—mention LDN as a therapeutic option for MS 2, 3. This complete absence from guideline recommendations is telling, especially when these guidelines extensively detail approved disease-modifying therapies like natalizumab, fingolimod, alemtuzumab, and dimethyl fumarate.
Lack of Objective Evidence for Inflammatory Control
While some research suggests LDN may have subjective benefits, the evidence fails to demonstrate impact on objective measures of MS inflammatory activity:
- A 2018 systematic review found that LDN studies in MS focus primarily on subjective measures like quality of life and self-reported pain, with "limited evidence for more objective measures" 4
- A 2016 retrospective study of 23 MS patients on LDN showed "no significant differences in clinical laboratory values, timed walking, or changes in magnetic resonance imaging" over 1-50 months 5
- Critically, none of the available studies demonstrate reduction in MRI-detected inflammatory lesions, gadolinium-enhancing lesions, or relapse rates—the standard markers of MS inflammatory activity 2
Mechanism Does Not Target MS Pathophysiology
The proposed mechanism of LDN—modulation of glial cells and Toll-like receptor 4 signaling 6, 7—differs fundamentally from established MS therapies that directly target lymphocyte trafficking, proliferation, or depletion. While one animal study showed reduced CD4+ T cell CNS infiltration in experimental autoimmune encephalomyelitis 8, this has not translated to demonstrated efficacy in controlling human MS inflammatory activity.
What the Evidence Actually Shows
The available research on LDN in MS is limited to:
- Symptom management: Possible benefits for fatigue, anxiety, and subjective pain 9, 10, 11
- Safety profile: Generally well-tolerated with minimal adverse effects 4, 5
- No disease modification: No evidence of reducing inflammatory lesions, preventing relapses, or slowing disability progression
A 2023 randomized controlled trial in arthritis patients found no efficacy for LDN in reducing nociceptive pain compared to placebo 12, raising questions about its effectiveness even for pain management.
Clinical Pitfalls to Avoid
- Do not substitute LDN for proven disease-modifying therapies: Patients with active inflammatory MS require treatments with demonstrated efficacy in reducing relapses and MRI activity
- Recognize the difference between symptom management and disease control: While LDN may help with fatigue or anxiety, this does not equate to controlling the underlying inflammatory process
- Beware of off-label use without evidence: The fact that LDN is "inexpensive and well-tolerated" 6 does not justify its use when effective alternatives exist
The Appropriate Approach
For MS patients with inflammatory activity, use FDA-approved disease-modifying therapies with proven efficacy on objective outcomes including:
- Reduction in gadolinium-enhancing lesions on MRI
- Decreased relapse rates
- Slowed disability progression
Monitor treatment response with annual brain MRI (or every 3-4 months for high-risk therapies) using contrast-enhanced T1-weighted and T2-weighted sequences to detect new or enlarging lesions 2.
If patients experience inadequate symptom control (fatigue, pain) despite effective disease-modifying therapy, LDN could theoretically be considered as an adjunctive symptomatic treatment, but this remains experimental and should not replace proven anti-inflammatory therapies.